Abstract
Anti-Tumor Necrosis Factor (TNF) agents were the first molecular targeting drugs developed for the treatment of rheumatoid arthritis (RA). Anti-TNF agents improve the clinical picture of severe RA patients, inhibit joint destruction and improve quality of life. In the 15 years since their introduction, they have become the preferred drug therapy for management of RA. The success of anti-TNF agents in the treatment of RA has resulted in the development of many drugs for other inflammatory diseases using the same molecular targeting concept. However, many unresolved issues surround the use of anti-TNF agents, including the risk for infection, primary non-responders, secondary loss of efficacy and pharmacoeconomical issues. This review focuses on the multifaceted impact of anti-TNF agents in the treatment of RA.
Keywords: Cytokine, inflammation, molecular target, rheumatoid arthritis, receptor.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:TNF as a Target of Inflammation in Rheumatoid Arthritis
Volume: 15 Issue: 2
Author(s): Hisashi Yamanaka
Affiliation:
Keywords: Cytokine, inflammation, molecular target, rheumatoid arthritis, receptor.
Abstract: Anti-Tumor Necrosis Factor (TNF) agents were the first molecular targeting drugs developed for the treatment of rheumatoid arthritis (RA). Anti-TNF agents improve the clinical picture of severe RA patients, inhibit joint destruction and improve quality of life. In the 15 years since their introduction, they have become the preferred drug therapy for management of RA. The success of anti-TNF agents in the treatment of RA has resulted in the development of many drugs for other inflammatory diseases using the same molecular targeting concept. However, many unresolved issues surround the use of anti-TNF agents, including the risk for infection, primary non-responders, secondary loss of efficacy and pharmacoeconomical issues. This review focuses on the multifaceted impact of anti-TNF agents in the treatment of RA.
Export Options
About this article
Cite this article as:
Yamanaka Hisashi, TNF as a Target of Inflammation in Rheumatoid Arthritis, Endocrine, Metabolic & Immune Disorders - Drug Targets 2015; 15 (2) . https://dx.doi.org/10.2174/1871530315666150316121808
DOI https://dx.doi.org/10.2174/1871530315666150316121808 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Therapeutic Potential of Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS: A Combination Approach with HAART
Current HIV Research Gene Expression Profiles in Human Autoimmune Disease
Current Pharmaceutical Design Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries
CNS & Neurological Disorders - Drug Targets MicroRNAs as Early Biomarkers in Obesity and Related Metabolic and Cardiovascular Diseases
Current Pharmaceutical Design Sustained Delivery of Interferons by Micro- and Nanosystems
Recent Patents on Materials Science Lymphadenopathy as a Prodrome for Systemic Lupus Erythematous
Current Rheumatology Reviews Current and Future Therapeutic Targets of Rheumatoid Arthritis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Biologics for the Treatment of Juvenile Idiopathic Arthritis
Current Medicinal Chemistry A Pathway and Approach to Biomarker Validation and Qualification for Osteoarthritis Clinical Trials
Current Drug Targets Role of Fc Receptors as a Therapeutic Target
Inflammation & Allergy - Drug Targets (Discontinued) Cardio-Rheumatology: Two Collaborating Disciplines to Deal with the Enhanced Cardiovascular Risk in Autoimmune Rheumatic Diseases
Current Vascular Pharmacology Vaccine Therapy Update for Pregnant, Immunocompromised, and Chronic Diseases Patients
Recent Patents on Inflammation & Allergy Drug Discovery CD248: Reviewing its Role in Health and Disease
Current Drug Targets TRP Channels in Vascular Disorders
Current Topics in Medicinal Chemistry Anti-IL-12/23 in Crohn's Disease: Bench and Bedside
Current Drug Targets Comparison of <i>In Vitro</i> and <i>In Vivo</i> Effects of Infliximab on Cytokine Production in Proliferating CD4+ T Cells in Patients with Rheumatoid Arthritis
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) The Sphingolipid Rheostat: A Potential Target for Improving Pancreatic Islet Survival and Function
Endocrine, Metabolic & Immune Disorders - Drug Targets Methotrexate Induced Pneumonitis: A Review Article
Current Respiratory Medicine Reviews Drug-Induced Liver Injury: Mechanisms, Types and Biomarkers
Current Medicinal Chemistry Recent Advances in the Development of Selective CB2 Agonists as Promising Anti-Inflammatory Agents
Current Medicinal Chemistry